Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment.
Young-Sil LeeHyunChul YounHyun-Ghang JeongTae-Jin LeeJi Won HanJoon Hyuk ParkKi Woong KimPublished in: Cost effectiveness and resource allocation : C/E (2021)
In our model, using amyloid-PET at the MCI stage was not cost-effective. Future advances in management of cognitive impairment would enhance QALYs, and consequently improve cost-effectiveness.